InflaRx N.V. (IFRX)vsRevolution Medicines Inc (RVMD)
IFRX
InflaRx N.V.
$2.09
+1.95%
HEALTHCARE · Cap: $337.47M
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates -7446% more annual revenue ($742,000 vs $-10,101). RVMD leads profitability with a 0.0% profit margin vs 0.0%. IFRX earns a higher WallStSmart Score of 38/100 (F).
IFRX
Hold38
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 352965.0%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : IFRX
The strongest argument for IFRX centers on Operating Margin, Debt/Equity, Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IFRX
The primary concerns for IFRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
IFRX carries more volatility with a beta of 2.52 — expect wider price swings.
IFRX is growing revenue faster at -80.8% — sustainability is the question.
IFRX generates stronger free cash flow (-3M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IFRX scores higher overall (38/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InflaRx N.V.
HEALTHCARE · BIOTECHNOLOGY · USA
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?